Fluvoxamine [1], a commonly prescribed drug to treat depression and Obsessive Compulsive Disorder (OCD) has been found to be effective in COVID-19 in early stage - within 7 days of developing symptoms.

Fluvoxamine tablet 100 mg BID for 10 days in early stage of the COVID-19 has been found to reduce the need of extended emergency room observation, hospitalization, ICU admission and ventilator.

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) and a Sigma-1 receptor (S1R) agonist, an essential inhibitor of cytokine production.

References

1. Hashimoto Y., et al. “Old Drug Fluvoxamine, new hope for COVID-19”. Archives of Psychiatry and Clinical Neuroscience (2021): 1-3.

Citation

Citation: Tapan K Chaudhuri and Richard Hoffler. “Fluvoxamine - A Potential New Drug to Treat Covid-19 in Early Stage". Acta Scientific Pharmaceutical Sciences 5.11 (2020):.

Copyright

Copyright: © 2020 Tapan K Chaudhuri and Richard Hoffler. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.